MET positive
|
Solid Tumor
|
MET positive
|
Solid Tumor
|
GST-HG16 Sensitive: C2 – Inclusion Criteria
|
GST-HG16 Sensitive: C2 – Inclusion Criteria
|
MET positive
|
NSCLC
|
MET positive
|
NSCLC
|
ABBV-399 Sensitive: C2 – Inclusion Criteria
|
ABBV-399 Sensitive: C2 – Inclusion Criteria
|
MET positive
|
SCCHN
|
MET positive
|
SCCHN
|
nivolumab Resistant: C3 – Early Trials
|
nivolumab Resistant: C3 – Early Trials
|
MET positive
|
Lung Non-Squamous Non-Small Cell Cancer
|
MET positive
|
Lung Non-Squamous Non-Small Cell Cancer
|
erlotinib + ABBV-399 Sensitive: C3 – Early Trials
|
erlotinib + ABBV-399 Sensitive: C3 – Early Trials
|
MET positive
|
Lung Non-Small Cell Squamous Cancer
|
MET positive
|
Lung Non-Small Cell Squamous Cancer
|
erlotinib + ABBV-399 Sensitive: C3 – Early Trials
|
erlotinib + ABBV-399 Sensitive: C3 – Early Trials
|
MET positive
|
NSCLC
|
MET positive
|
NSCLC
|
erlotinib + LY2875358 Sensitive: C3 – Early Trials
|
erlotinib + LY2875358 Sensitive: C3 – Early Trials
|
MET positive
|
Gastric Cancer
|
MET positive
|
Gastric Cancer
|
c-MET-targeted CAR-T immunotherapy Sensitive: D – Preclinical
|
c-MET-targeted CAR-T immunotherapy Sensitive: D – Preclinical
|